SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-17-110109
Filing Date
2017-04-04
Accepted
2017-04-04 16:02:58
Documents
7
Period of Report
2017-05-31

Document Format Files

Seq Description Document Type Size
1 PRE 14A d334253dpre14a.htm PRE 14A 670336
2 GRAPHIC g322141g21w10.jpg GRAPHIC 33374
3 GRAPHIC g322141g38l86.jpg GRAPHIC 23213
4 GRAPHIC g322141g54t09.jpg GRAPHIC 22635
5 GRAPHIC g322141g77a13.jpg GRAPHIC 23954
6 GRAPHIC g334253g21w10.jpg GRAPHIC 33374
7 GRAPHIC g334253g47k82.jpg GRAPHIC 25755
  Complete submission text file 0001193125-17-110109.txt   894962
Mailing Address AESCHENVORSTADT 36 BASEL V8 4051
Business Address AESCHENVORSTADT 36 BASEL V8 4051 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37923 | Film No.: 17738079
SIC: 2836 Biological Products, (No Diagnostic Substances)